2015

Appendix 3B – Exercise of Options

Appendix 3B – Exercise of options

Results of Meeting

Proteomics AGM Presentation

Proteomics International receives R&D Tax Incentive

Appendix 3B – Issue of Shortfall Options

Proteomics Targets Key Asian Markets

Appendix 4C – September 2015 Quarterly Report

Proteomics granted US Patent for Diagnostic Test

Proteomics Technical Presentation

Notice of Annual General Meeting/Proxy Form

Proteomics International Wins WA Industry and Export Award

Change of Directors’ Interest Notices

Initial Director’s Interest Notice

Proteomics International Laboratories Appoints New Director

Change of Directors’ Interest Notices

Completion of Entitlement Issue and Shortfall notice

Corporate Governance Statement and Appendix 4G

Appendix 3B – Release from escrow

Annual Report to shareholders

Entitlement Issue Prospectus Despatch

Release from escrow

Letter to Ineligible Shareholders – Entitlement Issue

Letter to Eligible Shareholders – Entitlement Issue

Non-renounceable Pro-rata Options Entitlement Issue

Entitlement Issue Prospectus

Appendix 3B – Entitlement Issue

Letter to option holders – Entitlement Issue

Investor Presentation – September 2015

Appendix 4E – Preliminary Final Report

Investor Presentation – August 2015

Appendix 4C – June 2015 Quarterly Report

Appendix 3B – Release from escrow

Appendix 3B – Release from escrow

Release from escrow

Investor Presentation – June 2015

Ground-breaking Predictive Test for Diabetic Kidney Disease

Release from escrow

Appendix 3B – Release from escrow

Release from escrow

Diagnostic Test Patent Accepted for Diabetic Kidney Disease

PILL appoints Global Head of Business Development

Appendix 3B – Release from escrow